CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Drug attack shows promise for tough prostate cancer
Disease control OngoingThis phase 2 trial tests whether adding the chemotherapy cabazitaxel to standard hormone therapy (abiraterone) can better control advanced prostate cancer that has spread and stopped responding to initial treatment. The study involves 223 men whose cancer progressed after docetax…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control OngoingThis phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to tame tough prostate cancer
Disease control OngoingThis phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo aims to slow bone metastases in prostate cancer
Disease control OngoingThis study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The tria…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells that carry a …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo therapy targets bone metastases in prostate cancer
Disease control OngoingThis phase 2 trial studies whether adding radium-223 to enzalutamide works better than enzalutamide alone in men with castration-resistant prostate cancer that has spread to bones. Enzalutamide blocks male hormones that fuel cancer growth, while radium-223 delivers targeted radia…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug duo takes on tough cancers
Disease control OngoingThis early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for hard-to-treat prostate cancer: adding immunotherapy to current drug
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab can help men whose advanced prostate cancer has stopped responding to the standard drug enzalutamide. About 58 men with castration-resistant prostate cancer that has spread will receive pembrolizumab while conti…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Targeted drug shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 c…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo pill targets Hard-to-Treat prostate cancer in men with SPOP mutation
Disease control OngoingThis phase 2 trial tests a fixed-dose combination of niraparib and abiraterone acetate plus prednisone in 8 men with metastatic castration-resistant prostate cancer that has a SPOP gene mutation. The drugs work by blocking cancer cell repair and reducing inflammation. The main go…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cocktail of cancer drugs tested in advanced tumors
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to slow tough prostate cancer
Disease control OngoingThis study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial tests whether combining golimumab (an anti-inflammatory drug) with apalutamide (a hormone blocker) can help men with castration-resistant prostate cancer that has spread. The study enrolled 8 participants and measures PSA reduction and tumor shrinkage. The goal…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough prostate cancer: drug cocktails under trial
Disease control OngoingThis study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Double-Drug attack on prostate cancer shows promise in early trial
Disease control OngoingThis phase III trial tests whether adding rucaparib to standard enzalutamide therapy helps men with metastatic castration-resistant prostate cancer live longer or delay cancer growth. The study involves 61 participants and compares the combination against enzalutamide alone. Rese…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Smart scans may boost prostate cancer radiation therapy
Disease control OngoingThis phase II trial tests whether using PSMA PET scans to select patients with castration-resistant prostate cancer that has spread to bones can improve the effectiveness of radium-223 therapy. Radium-223 is a radioactive drug that targets bone tumors. The study involves only 2 p…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Immunotherapy-Chemo combo targets tough neuroendocrine cancers
Disease control OngoingThis early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC